362:
22:
271:
Meena; Baum, Seth J; Borg, Brian; Ruane, Peter J; Thuluvath, Paul J; Gottwald, Mildred; Khan, Mujib; Chen, Charles; Melchor-Khan, Liza; Chang, William; DePaoli, Alex M; Ling, Lei; Lieu, Hsiao D (July 2022). "Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial".
186:
Babu, A.F.; Iannone, V.; Lok, J.; Gomez-Gallego, C.; D'Auria, G.; Vazquez-Uribe, R.; Pihlajamaki, J.; Sommer, M.; Hanhineva, K.; El-Nezami, H.; Kohlemainen, M. (August 2023). "An integrated understanding of the metabolic benefits of a novel double-targeted genetically engineered probiotic expressing
314:
Harrison, Stephen A.; Neff, Guy; Guy, Cynthia D.; Bashir, Mustafa R.; Paredes, Angelo H.; Frias, Juan P.; Younes, Ziad; Trotter, James F.; Gunn, Nadege T.; Moussa, Sam E.; Kohli, Anita; Nelson, Kristin; Gottwald, Mildred; Chang, William C.G.; Yan, Andrew Z.; DePaoli, Alex M.; Ling, Lei; Lieu, Hsiao
222:
Rinella, Mary E.; Lieu, Hsiao D.; Kowdley, Kris V.; Goodman, Zachary D.; Alkhouri, Naim; Lawitz, Eric; Ratziu, Vlad; Abdelmalek, Manal F.; Wong, Vincent Wai-Sun; Younes, Ziad H.; Sheikh, Aasim M.; Brannan, Donald; Freilich, Bradley; Membreno, Fernando; Sinclair, Marie; Melchor-Khan, Liza; Sanyal,
270:
Harrison, Stephen A; Abdelmalek, Manal F; Neff, Guy; Gunn, Nadege; Guy, Cynthia D; Alkhouri, Naim; Bashir, Mustafa R; Freilich, Bradley; Kohli, Anita; Khazanchi, Arun; Sheikh, Muhammad Y; Leibowitz, Mark; Rinella, Mary E; Siddiqui, Mohammad S; Kipnes, Mark; Moussa, Sam E; Younes, Ziad H; Bansal,
422:
317:"Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis"
403:
225:"A randomized, double-blind, placebo-controlled trial of Aldafermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis"
96:
166:
137:
427:
396:
389:
117:
296:
204:
338:
288:
252:
126:
328:
280:
242:
232:
196:
32:
146:
200:
247:
224:
373:
284:
416:
300:
208:
369:
333:
316:
237:
51:
41:
342:
292:
256:
71:
21:
361:
423:
Experimental drugs developed for non-alcoholic fatty liver disease
162:
223:
Arun J.; Ling, Lei; Harrison, Stephen A. (21 September 2023).
15:
377:
187:
aldafermin intervention with dietary change on NAFLD".
46:
36:
136:
116:
111:
95:
90:
82:
77:
125:
397:
8:
273:The Lancet Gastroenterology & Hepatology
70:
404:
390:
332:
246:
236:
145:
178:
69:
201:10.1016/j.atherosclerosis.2023.06.772
7:
358:
356:
14:
360:
20:
165:(FGF19) analogue developed for
1:
285:10.1016/S2468-1253(22)00017-6
167:non-alcoholic steatohepatitis
376:. You can help Knowledge by
334:10.1053/j.gastro.2020.08.004
238:10.1097/HEP.0000000000000607
163:fibroblast growth factor 19
444:
355:
35:, as no other articles
372:-related article is a
315:D. (January 2021).
74:
428:Pharmacology stubs
54:for suggestions.
44:to this page from
385:
384:
327:(1): 219–231.e1.
156:
155:
68:
67:
435:
406:
399:
392:
364:
357:
347:
346:
336:
321:Gastroenterology
311:
305:
304:
267:
261:
260:
250:
240:
219:
213:
212:
183:
149:
129:
75:
73:
63:
60:
49:
47:related articles
24:
16:
443:
442:
438:
437:
436:
434:
433:
432:
413:
412:
411:
410:
353:
351:
350:
313:
312:
308:
269:
268:
264:
221:
220:
216:
189:Atherosclerosis
185:
184:
180:
175:
152:
132:
107:
104:Investigational
86:NGM282; NGM-282
64:
58:
55:
45:
42:introduce links
25:
12:
11:
5:
441:
439:
431:
430:
425:
415:
414:
409:
408:
401:
394:
386:
383:
382:
365:
349:
348:
306:
279:(7): 603–616.
262:
214:
177:
176:
174:
171:
154:
153:
151:
150:
142:
140:
134:
133:
131:
130:
122:
120:
114:
113:
109:
108:
106:
105:
101:
99:
93:
92:
88:
87:
84:
80:
79:
66:
65:
52:Find link tool
28:
26:
19:
13:
10:
9:
6:
4:
3:
2:
440:
429:
426:
424:
421:
420:
418:
407:
402:
400:
395:
393:
388:
387:
381:
379:
375:
371:
366:
363:
359:
354:
344:
340:
335:
330:
326:
322:
318:
310:
307:
302:
298:
294:
290:
286:
282:
278:
274:
266:
263:
258:
254:
249:
244:
239:
234:
230:
226:
218:
215:
210:
206:
202:
198:
194:
190:
182:
179:
172:
170:
168:
164:
160:
148:
144:
143:
141:
139:
135:
128:
124:
123:
121:
119:
115:
110:
103:
102:
100:
98:
94:
89:
85:
81:
78:Clinical data
76:
62:
59:December 2023
53:
48:
43:
39:
38:
34:
29:This article
27:
23:
18:
17:
378:expanding it
370:pharmacology
367:
352:
324:
320:
309:
276:
272:
265:
228:
217:
192:
188:
181:
158:
157:
127:1616639-03-2
97:Legal status
91:Legal status
56:
30:
112:Identifiers
83:Other names
417:Categories
229:Hepatology
173:References
159:Aldafermin
147:IK9NYN31ZM
118:CAS Number
72:Aldafermin
50:; try the
37:link to it
301:247612032
209:261379804
40:. Please
343:32781086
293:35325622
257:37732990
248:10871650
195:: S32.
341:
299:
291:
255:
245:
207:
33:orphan
31:is an
368:This
297:S2CID
205:S2CID
161:is a
374:stub
339:PMID
289:PMID
253:PMID
138:UNII
329:doi
325:160
281:doi
243:PMC
233:doi
197:doi
193:379
419::
337:.
323:.
319:.
295:.
287:.
275:.
251:.
241:.
231:.
227:.
203:.
191:.
169:.
405:e
398:t
391:v
380:.
345:.
331::
303:.
283::
277:7
259:.
235::
211:.
199::
61:)
57:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
